New stock news | The prospectus of the Weizhao Semiconductor Hong Kong IPO is ineffective.
The listing prospectus of Shenzhen Weizhao Semiconductor Co., Ltd. (referred to as Weizhao Semiconductor) submitted on January 12, 2026, was valid for 6 months and expired on July 12, 2026.
Shenzhen Weizhao Semiconductor Co., Ltd. (referred to as Weizhao Semiconductor) submitted its Hong Kong stock prospectus on January 12, 2026, which expired on July 12, 2026, six months later. GF SEC served as its sponsor.
According to the prospectus previously disclosed, Weizhao Semiconductor is a leading Chinese provider of power semiconductor devices, focusing on the research, development, design, and sales of high-performance power semiconductor devices, especially WLCSP products, one of the company's main products. The product is known for its advanced semiconductor packaging technology, compact size, excellent heat dissipation performance, and impact resistance.
Related Articles
ABBISKO-B(02256): Hoya Pharmaceuticals announced that the new oral small molecule pan-KRAS inhibitor ABSK211 has received FDA approval for clinical trial application.
.png)
INSILICO (03696) and CMS (00867) have reached a new strategic partnership in the field of central nervous system drug development.
BEKE-W(02423) spent about 5 million dollars to repurchase 958,800 shares on July 10th.
ABBISKO-B(02256): Hoya Pharmaceuticals announced that the new oral small molecule pan-KRAS inhibitor ABSK211 has received FDA approval for clinical trial application.
INSILICO (03696) and CMS (00867) have reached a new strategic partnership in the field of central nervous system drug development.
BEKE-W(02423) spent about 5 million dollars to repurchase 958,800 shares on July 10th.
RECOMMEND
